Roche and Ionis have worked together for years. The two are currently collaborating on tominersen a type of drug called an antisense oligonucleotide that blocks the expression of a protein mutated in Huntingtons disease. That drug is in a Phase 2 trial measuring biologic signs of disease as well as patient function